[Skip to Navigation]
Invited Commentary
July 1, 2019

Treatment of Fatty Liver Disease—Time to Implement Common Sense Measures

Author Affiliations
  • 1Department of Medicine, University of California, San Francisco
  • 2Division of Gastroenterology, Department of Medicine, University of California, San Francisco
JAMA Intern Med. 2019;179(9):1272-1273. doi:10.1001/jamainternmed.2019.2244

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases in which excess fat deposits in the liver (steatosis, NAFL) are separate from but can progress to inflammation and fibrosis (nonalcoholic steatohepatitis, NASH), fibrosis, and cirrhosis. Nonalcoholic fatty liver disease has become a major public health issue, affecting about 25% of adults worldwide and two-thirds of adults with obesity.1 Hepatocellular carcinoma associated with NAFLD increased 10-fold between 2000 and 2010, and trends suggest that NAFLD will emerge as the leading cause of end-stage liver disease in the coming decades.2 Beyond liver disease, patients with NAFLD are at significant risk of cardiovascular morbidity and mortality.3

Add or change institution